infectious-disease-diagnostics
(4)
Pattern Bioscience wants to put bacteria on the clock
A hospital can start antibiotics long before it knows which ones will work. Pattern Bioscience is building a test that watches individual bacteria respond, aiming to turn days of uncertainty into hours.
Bradley Murray Is Turning a Wild Scientific Search Into a Clinical Routine
He learned to read genomes, helped build CRISPR programs, and sat on the investor's side of the table. Now Bradley Murray is betting that the future of diagnostics depends less on inspired guessing and more on disciplined execution.
Delve Bio Built One Test for 68,000 Suspects - Now It Wants Doctors to Use It Before the Guessing Game
The UCSF spinout turned an academic pathogen-hunting assay into a 48-hour clinical service. Its next challenge is bigger than sequencing: persuading hospitals to order one broad test earlier, without pretending every strange read is the answer.
Biotia
Biotia is a New York-based health-tech company that fights infectious diseases by combining next-generation DNA sequencing with AI-driven software. Its metagenomic platform identifies bacteria, fungi, parasites and viruses - plus antimicrobial-resistance markers - from a single sample against a curated database of more than 16,000 microbial species. Spun out of the Jacobs Technion-Cornell Institute at Cornell Tech and operating a CLIA-certified lab in New York City, Biotia turns a single microbiome test into an actionable clinical report to help providers diagnose hard-to-detect infections and support pathogen surveillance from the hospital to outer space.